Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) components.
DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Neuropathic Pain, historical and forecasted epidemiology as well as the Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Neuropathic Pain Report:
- In the UK, eight per cent of the general population experience neuropathic pain.
- The prevalence of chronic pain to be 16.6% and the prevalence of neuropathic pain was 3.2%.
- The United States has the highest percentage of prevalent diagnosed and treated patients.
- As per the International Association for the Study of Pain (2014–2015), of the 33 million people affected with HIV across the world, around 35% had neuropathic pain, which did not respond well to standard treatments.
- As per the article by Bouhassira (2018) titled “Neuropathic pain: Definition, assessment and epidemiology,” epidemiological studies have shown that their prevalence in the general population may be as high as 7–8%, accounting for 20–25% of individuals with chronic pain.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/neuropathic-pain-market
Key benefits of the Neuropathic Pain report:
- Neuropathic Pain market report covers a descriptive overview and comprehensive insight of the Neuropathic Pain epidemiology and Neuropathic Pain market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- Neuropathic Pain market report provides insights on the current and emerging therapies.
- Neuropathic Pain market report provides a global historical and forecasted market covering drug outreach in 7MM.
- Neuropathic Pain market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Neuropathic Pain market.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/neuropathic-pain-market
“It was observed that 67.5% of the patients with neuropathic pain were in the 65–74 age group.”
The primary goals of neuropathic pain treatment are to manage the pain as much as possible and to minimize the negative side-effects.
There are various neuropathic pain treatments available, and often it is a ‘trial and error’ process to find the best option for a person. Regular painkillers such as nonsteroidal anti-inflammatory drugs or NSAIDs (for example ibuprofen, aspirin and paracetamol) are usually not effective for neuropathic pain.
The key players in Neuropathic Pain market are:
- Daiichi Sankyo
- Regenacy Pharmaceuticals
- Lateral Pharma
- And many others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/neuropathic-pain-market
Neuropathic Pain Drugs covered:
- Mirogabalin/Tarlige
- Ricolinostat/HDAC6
- LAT8881
- And many others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/neuropathic-pain-market
Table of contents
1. Report Introduction
2. Executive Summary
3. Neuropathic Pain Market Overview at a Glance
4. Neuropathic Pain Disease Background and Overview
5. Case Reports
6. Neuropathic Pain Epidemiology Methodology
7. Neuropathic Pain Epidemiology and Patient Population
8. Neuropathic Pain Country-Wise Epidemiology
9. Neuropathic Pain Treatments & Medical Practices
10. Neuropathic Pain Marketed Products
10.1. Tarlige: Daiichi Sankyo
11. Neuropathic Pain Emerging Therapies
11.1. Key Cross Competition
11.2. Mirogabalin/Tarlige: Daiichi Sankyo (For CNP)
11.3. Ricolinostat/HDAC6: Regenacy Pharmaceuticals
11.4. LAT8881: Lateral Pharma
12. Neuropathic Pain Market Size
13. 7MM Neuropathic Pain Country-Wise Market Analysis
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Reimbursement
18. Appendix
19. Neuropathic Pain Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/neuropathic-pain-market
Related Reports:
Neuropathic Pain Pipeline
The Neuropathic Pain report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuropathic Pain across the complete product development cycle, including all clinical and nonclinical stages.
Neuropathic Pain Epidemiology
The Neuropathic Pain epidemiology covered in the report provides historical as well as forecasted Neuropathic Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neuropathic-pain-market